199 related articles for article (PubMed ID: 12475684)
1. Recurrence of prostate adenocarcinoma presenting with multiple myeloma simulating skeletal metastases of prostate adenocarcinoma.
Huang E; Teh BS; Saleem A; Butler EB
Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475684
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma of the prostate with multiple osteolytic metastases simulating multiple myeloma. A case report.
Maharaj B; Kalideen JM; Leary WP; Pudifin DJ
S Afr Med J; 1986 Aug; 70(4):227-8. PubMed ID: 3738661
[TBL] [Abstract][Full Text] [Related]
3. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic challenges of clonal heterogeneity in prostate cancer.
Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
[No Abstract] [Full Text] [Related]
5. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.
Safa AA; Reese DM; Carter DM; Phillipson J; Smith R; Dougherty S
Am J Clin Oncol; 1998 Aug; 21(4):323-6. PubMed ID: 9708626
[TBL] [Abstract][Full Text] [Related]
6. Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results.
Leibowitz SB; Oh WK
J Urol; 2003 Oct; 170(4 Pt 1):1305. PubMed ID: 14501750
[No Abstract] [Full Text] [Related]
7. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Mystakidou K; Katsouda E; Parpa E; Vlahos L
J Pain Palliat Care Pharmacother; 2005; 19(3):41-5. PubMed ID: 16219610
[TBL] [Abstract][Full Text] [Related]
8. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic prostate cancer associated with low levels of prostate-specific antigen].
Diaz S; Salirrosas M
Rev Peru Med Exp Salud Publica; 2012; 29(4):541-4. PubMed ID: 23338642
[TBL] [Abstract][Full Text] [Related]
10. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P; Steurer S; Huland H; Graefen M
J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
[No Abstract] [Full Text] [Related]
11. Relapsing Prostate Cancer: Castrate or Cure?
Tharmalingam H; Choudhury A
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1095-1096. PubMed ID: 29722651
[No Abstract] [Full Text] [Related]
12. Coexisting prostate adenocarcinoma with multiple myeloma: A rare case report.
Vyas Y; Salkar A; Bothale AK
Indian J Pathol Microbiol; 2018; 61(3):434-436. PubMed ID: 30004075
[TBL] [Abstract][Full Text] [Related]
13. Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
Patel V; Castell FA; Akinwunmi J; Francis I; Chandrasekharan L; Malhotra R
Orbit; 2010 Aug; 29(4):213-5. PubMed ID: 20812840
[TBL] [Abstract][Full Text] [Related]
14. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
[No Abstract] [Full Text] [Related]
15. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
16. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
18. Benign positive margins after radical prostatectomy means a poor prognosis--pro.
Djavan B; Milani S; Fong YK
Urology; 2005 Feb; 65(2):218-20. PubMed ID: 15708025
[No Abstract] [Full Text] [Related]
19. Evaluating the return of prostatic adenocarcinoma.
Berry MG; Feneley MR; Domizio P; Britton KE; Badenoch DF
J R Soc Med; 1998 Dec; 91(12):641-3. PubMed ID: 10730114
[No Abstract] [Full Text] [Related]
20. Prostatic carcinoma.
Lawton CA; Grignon D; Newhouse JH; Schellhammer PF; Kuban DA
Radiographics; 1999; 19(1):185-203. PubMed ID: 9925399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
